vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and NexPoint Residential Trust, Inc. (NXRT). Click either name above to swap in a different company.
NexPoint Residential Trust, Inc. is the larger business by last-quarter revenue ($62.1M vs $47.7M, roughly 1.3× IRONWOOD PHARMACEUTICALS INC). On growth, NexPoint Residential Trust, Inc. posted the faster year-over-year revenue change (-2.7% vs -47.3%). Over the past eight quarters, NexPoint Residential Trust, Inc.'s revenue compounded faster (-4.1% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
NexPoint Residential Trust, Inc. is a publicly traded real estate investment trust focused on acquiring, renovating, and operating multifamily residential properties primarily across high-growth Sun Belt markets in the United States. Its portfolio consists mainly of affordable and mid-tier apartment communities, targeting steady rental income growth and long-term asset value appreciation for investors.
IRWD vs NXRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $62.1M |
| Net Profit | $-2.3M | — |
| Gross Margin | — | — |
| Operating Margin | 14.3% | 8.4% |
| Net Margin | -4.8% | — |
| Revenue YoY | -47.3% | -2.7% |
| Net Profit YoY | -200.9% | — |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $62.1M | ||
| Q3 25 | $122.1M | $62.8M | ||
| Q2 25 | $85.2M | $63.1M | ||
| Q1 25 | $41.1M | $63.2M | ||
| Q4 24 | $90.5M | $63.8M | ||
| Q3 24 | $91.6M | $64.1M | ||
| Q2 24 | $94.4M | $64.2M | ||
| Q1 24 | $74.9M | $67.6M |
| Q4 25 | $-2.3M | — | ||
| Q3 25 | $40.1M | $-7.8M | ||
| Q2 25 | $23.6M | $-7.0M | ||
| Q1 25 | $-37.4M | $-6.9M | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $3.6M | $-8.9M | ||
| Q2 24 | $-860.0K | $10.6M | ||
| Q1 24 | $-4.2M | $26.3M |
| Q4 25 | 14.3% | 8.4% | ||
| Q3 25 | 61.8% | 11.8% | ||
| Q2 25 | 53.2% | 12.5% | ||
| Q1 25 | -70.7% | 11.7% | ||
| Q4 24 | 34.8% | 18.0% | ||
| Q3 24 | 28.0% | 8.7% | ||
| Q2 24 | 26.5% | 39.7% | ||
| Q1 24 | 14.7% | 60.7% |
| Q4 25 | -4.8% | — | ||
| Q3 25 | 32.8% | -12.4% | ||
| Q2 25 | 27.7% | -11.1% | ||
| Q1 25 | -90.9% | -10.9% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 4.0% | -13.8% | ||
| Q2 24 | -0.9% | 16.5% | ||
| Q1 24 | -5.6% | 38.9% |
| Q4 25 | $0.01 | — | ||
| Q3 25 | $0.23 | $-0.31 | ||
| Q2 25 | $0.14 | $-0.28 | ||
| Q1 25 | $-0.23 | $-0.27 | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $0.02 | $-0.35 | ||
| Q2 24 | $-0.01 | $0.40 | ||
| Q1 24 | $-0.03 | $1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $13.7M |
| Total DebtLower is stronger | — | $1.6B |
| Stockholders' EquityBook value | $-261.8M | $295.5M |
| Total Assets | $396.9M | $1.9B |
| Debt / EquityLower = less leverage | — | 5.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $13.7M | ||
| Q3 25 | $140.4M | $10.8M | ||
| Q2 25 | $92.9M | $13.6M | ||
| Q1 25 | $108.5M | $23.7M | ||
| Q4 24 | $88.6M | $23.1M | ||
| Q3 24 | $88.2M | $17.4M | ||
| Q2 24 | $105.5M | $21.3M | ||
| Q1 24 | $121.5M | $37.2M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | $1.5B |
| Q4 25 | $-261.8M | $295.5M | ||
| Q3 25 | $-264.2M | $322.9M | ||
| Q2 25 | $-308.2M | $347.9M | ||
| Q1 25 | $-334.1M | $379.9M | ||
| Q4 24 | $-301.3M | $410.4M | ||
| Q3 24 | $-311.3M | $447.1M | ||
| Q2 24 | $-321.7M | $491.1M | ||
| Q1 24 | $-330.5M | $512.8M |
| Q4 25 | $396.9M | $1.9B | ||
| Q3 25 | $396.1M | $1.8B | ||
| Q2 25 | $342.9M | $1.9B | ||
| Q1 25 | $327.2M | $1.9B | ||
| Q4 24 | $350.9M | $1.9B | ||
| Q3 24 | $389.5M | $2.0B | ||
| Q2 24 | $395.6M | $2.0B | ||
| Q1 24 | $438.8M | $2.0B |
| Q4 25 | — | 5.39× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.92× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $83.6M |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $83.6M | ||
| Q3 25 | $47.6M | $29.3M | ||
| Q2 25 | $-15.1M | $19.9M | ||
| Q1 25 | $20.0M | $28.3M | ||
| Q4 24 | $15.2M | $73.6M | ||
| Q3 24 | $9.9M | $27.8M | ||
| Q2 24 | $33.5M | $19.7M | ||
| Q1 24 | $45.0M | $19.7M |
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | 156.3% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | -17.7% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 35.4% | — | ||
| Q1 24 | 60.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | -0.64× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.74× | — | ||
| Q3 24 | 2.71× | — | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 0.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
